newsfilter
← Latest News
GlobeNewswire·

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectivelySurpassed milestone of more than 10,000 patients